Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.42 |
| ▸ | CTSS | P25774 | 11/20 | 0.42 |
| ▸ | CTSB | P07858 | 11/20 | 0.42 |
| ▸ | CTSK | P43235 | 7/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6182101 | 0.75 | PRKAB2 (0.49) | NAMPT | |
| Trifluoroacetic Acid SCHEMBL6183907 | 0.71 | FAAH (0.46) | — | |
| SCHEMBL7482944 | 0.69 | JAK2 (0.43) | CTSLCTSSCTSBCTSKMAPK8 | |
| SCHEMBL7482953 | 0.67 | CTSL (0.34) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6183364 | 0.67 | CTSB (0.35) | CTSLCTSSCTSBCTSK | |
| SCHEMBL7447948 | 0.67 | NAMPT (0.40) | CTSLCTSSCTSBCTSKNAMPT | |
| SCHEMBL6183132 | 0.66 | GAA (0.48) | NAMPT | |
| SCHEMBL7434370 | 0.66 | CASR (0.46) | CTSLCTSSCTSBCTSKEPHX2 | |
| SCHEMBL6182151 | 0.65 | NAMPT (0.44) | CTSSNAMPT | |
| SCHEMBL6184516 | 0.65 | KDM4E (0.44) | EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSL 14/4885CTSS 10/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.